Moderna (MRNA) Tax Provisions (2018 - 2026)

Moderna (MRNA) has 9 years of Tax Provisions data on file, last reported at $9.0 million in Q1 2026.

• On a quarterly basis, Tax Provisions rose 28.57% year-over-year to $9.0 million in Q1 2026; TTM through Mar 2026 was $56.0 million, a 214.29% increase from a year earlier, with the FY2025 full-year figure at $54.0 million, up 217.39% from the prior year.
• Tax Provisions for Q1 2026 stood at $9.0 million, down from $27.0 million in the prior quarter.
• Over the last five years, Tax Provisions for MRNA reached as high as $1.7 billion in Q3 2023 and fell as low as -$384.0 million in Q1 2023.
• Historically, Tax Provisions has averaged $125.1 million across 5 years, with a median of $9.5 million in 2024.
• Across the five-year window, Tax Provisions soared 1366.67% in 2022 and slumped 233.21% in 2023, its largest moves.
• Year by year, Tax Provisions stood at $190.0 million in 2022, then sank by 177.37% to -$147.0 million in 2023, then jumped by 56.46% to -$64.0 million in 2024, then jumped by 142.19% to $27.0 million in 2025, then slumped by 66.67% to $9.0 million in 2026.
• Per Business Quant data, the three most recent Tax Provisions figures were $9.0 million in Q1 2026, $27.0 million in Q4 2025, and $13.0 million in Q3 2025.